Why Editas Medicine Stock Jumped Again Today
Shares of Editas Medicine (NASDAQ: EDIT) were jumping 10.5% as of 3:26 p.m. EST on Tuesday. This marked the second consecutive day of strong momentum after the biotech presented new data for its experimental gene-editing therapy EDIT-301 at the American Society of Hematology (ASH) annual meeting last weekend.
It's understandable why investors continue to be bullish about Editas' prospects. The company's update at ASH highlighted promising preclinical data for EDIT-301 in treating sickle cell disease with high levels of gene editing and reduction in the sickling of cells. Editas also reported good news about its manufacturing process for the gene-editing therapeutic candidate, stating that the large-scale process was "shown to be consistent and robust."
Image source: Getty Images.
Source Fool.com
